MX337594B - Formulaciones de quinonas para tratamiento de padecimientos oftalmicos. - Google Patents
Formulaciones de quinonas para tratamiento de padecimientos oftalmicos.Info
- Publication number
- MX337594B MX337594B MX2012012518A MX2012012518A MX337594B MX 337594 B MX337594 B MX 337594B MX 2012012518 A MX2012012518 A MX 2012012518A MX 2012012518 A MX2012012518 A MX 2012012518A MX 337594 B MX337594 B MX 337594B
- Authority
- MX
- Mexico
- Prior art keywords
- quinones
- formulation
- treatment
- formula
- formulations
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 5
- 150000004053 quinones Chemical class 0.000 title abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title 1
- 208000014674 injury Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 230000008733 trauma Effects 0.000 abstract 2
- 201000002169 Mitochondrial myopathy Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32854610P | 2010-04-27 | 2010-04-27 | |
| US39369310P | 2010-10-15 | 2010-10-15 | |
| PCT/US2011/033983 WO2011137126A1 (en) | 2010-04-27 | 2011-04-26 | Formulations of quinones for the treatment of ophthalmic diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012012518A MX2012012518A (es) | 2012-12-17 |
| MX337594B true MX337594B (es) | 2016-03-11 |
Family
ID=44861894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012012518A MX337594B (es) | 2010-04-27 | 2011-04-26 | Formulaciones de quinonas para tratamiento de padecimientos oftalmicos. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20130109759A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2563352A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5902673B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN105147651A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2011245384C1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112012027543A8 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2797581A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201201465A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX337594B (cg-RX-API-DMAC7.html) |
| MY (1) | MY183449A (cg-RX-API-DMAC7.html) |
| SG (2) | SG10201801321XA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011137126A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201208535B (cg-RX-API-DMAC7.html) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005033093A1 (en) | 2003-09-19 | 2005-04-14 | Galileo Pharmaceuticals, Inc. | 7,8-bicycloalkyl-chroman derivatives |
| DK2471530T3 (en) | 2005-06-01 | 2017-04-10 | Edison Pharmaceuticals Inc | REDOXACTIVE THERAPEUTIC AGENTS FOR THE TREATMENT OF MITOCONDARY DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS |
| EP1986636B1 (en) | 2006-02-22 | 2013-04-24 | Edison Pharmaceuticals, Inc. | Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases |
| HUE028502T2 (en) | 2007-11-06 | 2016-12-28 | Edison Pharmaceuticals Inc | 4- (P-Quinonyl) -2-hydroxybutanamide derivatives for the treatment of mitochondrial diseases |
| EP2237664A4 (en) * | 2008-01-08 | 2013-05-22 | Edison Pharmaceuticals Inc | (HET) ARYL-p-CHINONE DERIVATIVES FOR THE TREATMENT OF OCHONDRIAL DISEASES |
| US8716527B2 (en) | 2008-03-05 | 2014-05-06 | Edison Pharmaceuticals, Inc. | 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases |
| US8716486B2 (en) * | 2008-06-25 | 2014-05-06 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
| LT3827815T (lt) | 2008-09-10 | 2023-10-10 | Ptc Therapeutics, Inc. | Psichologinių raidos sutrikimų gydymas oksidacijos redukcijos atžvilgiu aktyviais vaistais |
| US10039722B2 (en) | 2008-10-14 | 2018-08-07 | Bioelectron Technology Corporation | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
| ES2553557T3 (es) | 2008-10-28 | 2015-12-10 | Edison Pharmaceuticals, Inc. | Proceso para la producción de alfa-tocotrienol y derivados |
| HUE037574T2 (hu) | 2009-04-28 | 2018-09-28 | Bioelectron Tech Corp | Leber-féle örökletes optikus neuropátia és domináns optikus atrofia kezelése tokotrienol kinonokkal |
| US20110207828A1 (en) * | 2009-08-26 | 2011-08-25 | Miller Guy M | Methods for the prevention and treatment of cerebral ischemia |
| JP2013523816A (ja) * | 2010-04-06 | 2013-06-17 | エジソン ファーマシューティカルズ， インコーポレイテッド | 毛細血管拡張性運動失調症の治療 |
| MY183449A (en) * | 2010-04-27 | 2021-02-18 | Bioelectron Tech Corp | Formulations of quinones for the treatment of ophthalmic diseases |
| WO2012174286A1 (en) | 2011-06-14 | 2012-12-20 | Edison Pharmaceuticals, Inc. | Catechol derivatives for treatment of oxidative stress diseases |
| WO2013013078A1 (en) | 2011-07-19 | 2013-01-24 | Edison Pharmeceuticals, Inc. | Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols |
| US9629815B2 (en) | 2012-09-07 | 2017-04-25 | Bioelectron Technology Corporation | Benzoquinone derivatives for treating oxidative stress disorders |
| US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
| CA2906145A1 (en) | 2013-03-15 | 2014-09-18 | Edison Pharmaceuticals, Inc. | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders |
| US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
| US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| NZ733528A (en) | 2014-12-16 | 2021-07-30 | Ptc Therapeutics Inc | Polymorphic and amorphous forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide |
| JP7117241B2 (ja) | 2015-12-16 | 2022-08-12 | ピーティーシー セラピューティクス， インコーポレイテッド | 混合されたトコール組成物からアルファ－トコトリエノールを富化するための改良された方法 |
| CA3008849A1 (en) | 2015-12-17 | 2017-06-22 | Bioelectron Technology Corporation | Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩 |
| US11260048B2 (en) | 2017-10-03 | 2022-03-01 | The Schepens Eye Research Institute, Inc. | Compounds and compositions for inhibiting retinal pigment epithelium degeneration and methods using the same |
| HUE066196T2 (hu) | 2018-10-17 | 2024-07-28 | Ptc Therapeutics Inc | 2,3,5-trimetil-6-nonilciklohexa-2,5-dién-1,4-dion alfa-szinukleinopátiák, tauopátiák és egyéb rendellenességek szuppresszálására és kezelésére |
| JP7705106B2 (ja) * | 2019-05-28 | 2025-07-09 | ナノ－ネオ リミテッド | 網膜症を治療するための組成物及び方法 |
| CA3225266A1 (en) | 2021-07-08 | 2023-01-12 | Swathi PINNAMANENI | Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione |
| WO2025231245A1 (en) * | 2024-05-02 | 2025-11-06 | Stealth Biotherapeutics Inc. | Use of substituted 1,4 benzoquinones to treat alpha-synucleinopathies |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2471530T3 (en) * | 2005-06-01 | 2017-04-10 | Edison Pharmaceuticals Inc | REDOXACTIVE THERAPEUTIC AGENTS FOR THE TREATMENT OF MITOCONDARY DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS |
| EP1924292A2 (en) * | 2005-09-16 | 2008-05-28 | Allergan, Inc. | Compositions and methods for the intraocular transport of therapeutic agents |
| EP1986636B1 (en) * | 2006-02-22 | 2013-04-24 | Edison Pharmaceuticals, Inc. | Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases |
| LT3827815T (lt) * | 2008-09-10 | 2023-10-10 | Ptc Therapeutics, Inc. | Psichologinių raidos sutrikimų gydymas oksidacijos redukcijos atžvilgiu aktyviais vaistais |
| US20110207828A1 (en) * | 2009-08-26 | 2011-08-25 | Miller Guy M | Methods for the prevention and treatment of cerebral ischemia |
| JP2013523816A (ja) * | 2010-04-06 | 2013-06-17 | エジソン ファーマシューティカルズ， インコーポレイテッド | 毛細血管拡張性運動失調症の治療 |
| MY183449A (en) * | 2010-04-27 | 2021-02-18 | Bioelectron Tech Corp | Formulations of quinones for the treatment of ophthalmic diseases |
-
2011
- 2011-04-26 MY MYPI2012004738A patent/MY183449A/en unknown
- 2011-04-26 EP EP11775506.6A patent/EP2563352A4/en not_active Withdrawn
- 2011-04-26 JP JP2013508167A patent/JP5902673B2/ja not_active Expired - Fee Related
- 2011-04-26 CA CA2797581A patent/CA2797581A1/en not_active Abandoned
- 2011-04-26 SG SG10201801321XA patent/SG10201801321XA/en unknown
- 2011-04-26 WO PCT/US2011/033983 patent/WO2011137126A1/en not_active Ceased
- 2011-04-26 BR BR112012027543A patent/BR112012027543A8/pt not_active IP Right Cessation
- 2011-04-26 AU AU2011245384A patent/AU2011245384C1/en not_active Ceased
- 2011-04-26 SG SG2012079323A patent/SG185046A1/en unknown
- 2011-04-26 EA EA201201465A patent/EA201201465A1/ru unknown
- 2011-04-26 CN CN201510490746.XA patent/CN105147651A/zh active Pending
- 2011-04-26 CN CN2011800317444A patent/CN102985083A/zh active Pending
- 2011-04-26 MX MX2012012518A patent/MX337594B/es active IP Right Grant
- 2011-04-26 US US13/643,542 patent/US20130109759A1/en not_active Abandoned
-
2012
- 2012-11-13 ZA ZA2012/08535A patent/ZA201208535B/en unknown
-
2016
- 2016-03-10 JP JP2016046881A patent/JP6266674B2/ja not_active Expired - Fee Related
-
2017
- 2017-01-17 US US15/407,831 patent/US20170354618A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011245384A1 (en) | 2012-12-06 |
| SG185046A1 (en) | 2012-12-28 |
| JP2016106144A (ja) | 2016-06-16 |
| US20170354618A1 (en) | 2017-12-14 |
| US20130109759A1 (en) | 2013-05-02 |
| JP2013525443A (ja) | 2013-06-20 |
| EP2563352A4 (en) | 2013-11-13 |
| SG10201801321XA (en) | 2018-04-27 |
| WO2011137126A1 (en) | 2011-11-03 |
| JP6266674B2 (ja) | 2018-01-24 |
| MX2012012518A (es) | 2012-12-17 |
| EA201201465A1 (ru) | 2013-04-30 |
| CN105147651A (zh) | 2015-12-16 |
| EP2563352A1 (en) | 2013-03-06 |
| AU2011245384B2 (en) | 2016-02-18 |
| AU2011245384C1 (en) | 2016-09-01 |
| CA2797581A1 (en) | 2011-11-03 |
| CN102985083A (zh) | 2013-03-20 |
| MY183449A (en) | 2021-02-18 |
| JP5902673B2 (ja) | 2016-04-13 |
| BR112012027543A2 (pt) | 2019-05-28 |
| ZA201208535B (en) | 2016-06-29 |
| BR112012027543A8 (pt) | 2019-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY183449A (en) | Formulations of quinones for the treatment of ophthalmic diseases | |
| MX2011011310A (es) | Formulacion de tocotrienol quinonas para el tratamiento de enfermedades oftalmicas. | |
| WO2014096425A3 (en) | Prodrugs of monomethyl fumarate (mmf) | |
| NZ704247A (en) | Compositions and treatment for eye diseases and disorders | |
| CA2711696C (en) | Therapeutic compositions for treatment of ocular inflammatory disorders | |
| WO2012009171A3 (en) | Compositions and methods of treatment of corneal endothelium disorders | |
| HK1206297A1 (en) | Pharmaceutical compositions for combination therapy | |
| MY171920A (en) | Prevention and treatment of ocular conditions | |
| AU2012277802A8 (en) | Novel inhibitor compounds of phosphodiesterase type 10A | |
| MX2013011908A (es) | Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank. | |
| HK1213888A1 (zh) | 治療化合物和組合物以及其作為pkm2調節劑的用途 | |
| MX361858B (es) | Formulación oftálmica de lípido polioxilo o de ácido graso polioxilo y tratamiento de padecimientos oculares. | |
| WO2012080497A3 (en) | Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases | |
| PH12014502218A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| AU2013218357A8 (en) | Tetrahydro-quinazolinone derivatives as TANK and PARP inhibitors | |
| TN2014000046A1 (en) | Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one | |
| EP4420722A3 (en) | Modified fibroblast growth factors for the treatment of ocular disorders | |
| MX2013002121A (es) | Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3. | |
| MX2013002118A (es) | 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. | |
| MX356317B (es) | Tratamiento de síntomas asociados a gastroparesia femenina. | |
| WO2014070696A3 (en) | Treatment of chronic dermal inflammatory with norketotifen | |
| AU2014352875A8 (en) | Gastrin antagonists (eg YF476, netazepide) for treatment and prevention of osteoporosis | |
| WO2017129577A8 (en) | Ophthalmic gabapentin for the treatment of corneal ulcers | |
| AU2014216273A8 (en) | Topical ocular analgesic agents | |
| WO2013049272A3 (en) | Composition and method for treatment of symptoms associated with various skin conditions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |